Please login to the form below
phase 2 trial
This page shows the latest phase 2 trial news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly to make bebtelovimab commercially available to US states from August
The EUA was based on the results from Lilly’s phase 2 BLAZE-4 clinical trial, which demonstrated that bebtelovimab retained full neutralising activity against Omicron, the current predominant strain of ... A trial led by The University of Oxford also
Latest news
-
Pfizer and BioNTech initiate phase 2 study of ‘enhanced’ COVID-19 vaccine
Pfizer and BioNTech have initiated a phase 2 study evaluating a new version of the COVID-19 vaccine that the companies hope will better protect against the virus. ... The application followed positive results from a phase 2/3 trial, which found that a
-
Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma
The approval was based upon efficacy and safety data taken from the phase 2/3 RELATIVITY-047 trial. ... Patients involved in the RELATIVITY-047 trial were enrolled regardless of their tumour cell PD-L1 expression.
-
EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
Results from Bavarian Nordic’s phase 2 trial, which enrolled healthy adult volunteers aged 18-50 years, showed a significant reduction in viral load in MVA-BN RSV vaccinated subjects compared ... Strong results were also previously reported from a
-
Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
The EUA was based on the results from Lilly’s phase 2 BLAZE-4 clinical trial which demonstrated that bebtelovimab retained full neutralising activity against Omicron, the current predominant strain of ... A trial led by The University of Oxford also
-
Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
In June, the companies shared positive results from a phase 2/3 trial of two Omicron-adapted vaccine candidates, demonstrating the safety, tolerability and immunogenicity of the two candidates, and plan ... older. The FDA granted Pfizer and BioNTech
More from news
Approximately 0 fully matching, plus 319 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
As of 20 July, Synairgen revealed positive phase 2 trial results. ... share price on the day of the trial.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... With the latest phase 2 data,
-
Developing a COVID-19 vaccine
To win approval for public use, a larger phase 2 trial is need, which Moderna says is already in the planning stages and could start within a few months. ... The EMA has acknowledged the impact the pandemic may have on clinical trails and trial
-
Rethinking trials: the pros and cons of protocol amendments
AstraZeneca spokesman Matthew Kent said: “The BICLA was chosen as the primary endpoint for TULIP 2, following a full evaluation of the previous phase e trial TULIP 1, which did not ... The patient sampling size increases, as well, increasing the
-
Integrating patient reported outcomes into clinical trials
MyoKardia is gathering PROs in its phase 2 hypertrophic cardiomyopathy trial. ... Cara Therapeutics put two questionnaires about itching at the centre of its phase 3 pruritus trial.
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
In its earlier phase 1 monotherapy trial, TAVO demonstrated a 46% response rate in untreated lesions in metastatic melanoma. ... Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Gilead announces positive Biktarvy data for HIV and hepatitis B
- Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
- Medscape Education Receives Joint Accreditation with Commendation to Deliver Continuing Education for Healthcare Providers
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
- NHS England to roll out continuous glucose monitors to all those with type 1 diabetes
- Sanofi and Innovent Biologics to develop oncology drugs for patients in China
- WHO launches funding appeal for greater Horn of Africa prompted by food crisis
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Animation: Living With
- The journey from the patient's perspective...
- Achieving communication excellence by targeting the right channel at the right time
- By Danny Buckland...
- 6 trends shaping the future of personalized medicine
- Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
